Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition

Tim Kong, Angelo B.A. Laranjeira, Taylor B. Collins, Elisa S. De Togni, Abigail J. Wong, Mary C. Fulbright, Marianna Ruzinova, Hamza Celik, Grant A. Challen, Daniel A.C. Fisher, Stephen Oh

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Targeted inhibitors of JAκ2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone persists and remains susceptible to disease transformation. These observations suggest that targeting alternative dysregulated signaling pathways may provide therapeutic benefit. Previous studies identified NFκB pathway hyperactivation in myelofibrosis (MF) and secondary acute myeloid leukemia (sAML) that was insensitive to JAκ2 inhibition. Here, we provide evidence that NFκB pathway inhibition via pevonedistat targets malignant cells in MPN patient samples as well as in MPN and patient-derived xenograft mouse models that are nonredundant with ruxolitinib. Colony forming assays revealed preferential inhibition of MF colony growth compared with normal colony formation. In mass cytometry studies, pevonedistat blunted canonical TNFa responses in MF and sAML patient CD341 cells. Pevonedistat also inhibited hyperproduction of inflammatory cytokines more effectively than ruxolitinib. Upon pevonedistat treatment alone or in combination with ruxolitinib, MPN mouse models exhibited reduced disease burden and improved survival. These studies demonstrating efficacy of pevonedistat in MPN cells in vitro as well as in vivo provide a rationale for therapeutic inhibition of NFκB signaling for MF treatment. Based on these findings, a Phase 1 clinical trial combining pevonedistat with ruxolitinib has been initiated.

Original languageEnglish
Pages (from-to)611-623
Number of pages13
JournalBlood Advances
Volume6
Issue number2
DOIs
StatePublished - Jan 25 2022

Fingerprint

Dive into the research topics of 'Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition'. Together they form a unique fingerprint.

Cite this